Loading
Most cancer patients are older and have other illnesses, but nearly all animal experiments use young healthy mice. Results may not transfer.
Ageing changes immune function, drug metabolism, marrow reserve and the tumour microenvironment; obesity and diabetes alter drug distribution and immunotherapy response. Efficacy and toxicity studies in aged, obese or comorbid animals cost more and take longer, so they are rarely done. Requiring at least one aged-cohort confirmation before first-in-human studies of immunotherapies would be a targeted change.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, Immune checkpoint inhibitors.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients.